AusCann Group Holdings Ltd researches, develops, and commercializes various cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. It offers tetrahydrocannabinol and cannabidiol powder-based hard-shell capsules using Neuvis technology platform for the treatment of pain and related indications; CPAT-01, a liquid, oral veterinary medicine to treat pain and inflammation in dogs; and DermaCann, a liquid oral oil formulation containing CBD for healthy skin and immune function in dogs. The company is headquartered in West Perth, Australia.